These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 10262071)

  • 21. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2002 Oct; 67(194):62354-70. PubMed ID: 12369590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug enforcement administration liability for false arrest of physician.
    Brushwood DB
    J Pain Palliat Care Pharmacother; 2009; 23(2):156-62. PubMed ID: 19492217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health systems agency and state health planning and development agency reviews; certificate of need programs--PHS. Notice of proposed rulemaking.
    Fed Regist; 1983 Aug; 48(155):36402-15. PubMed ID: 10261491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2003 and inclusion of registered nurses in the personnel provision of the critical access hospital emergency services requirement for frontier areas and remote locations. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2002 Dec; 67(251):79965-80184. PubMed ID: 12510665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule.
    Fed Regist; 2000 Apr; 65(79):21645-7. PubMed ID: 11010670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Registration and reregistration application fees. Confirmation of final rule, remanded for further notice and comment, and response to comments.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2002 Aug; 67(154):51987-52007. PubMed ID: 12194173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Facsimile transmission of prescriptions for patients enrolled in hospice programs. Drug Enforcement Administration (DEA), Justice. Final rule.
    Fed Regist; 2001 Jan; 66(8):2214-5. PubMed ID: 11503757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Mar; 69(53):12794-7. PubMed ID: 15029891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exemption of chemical mixtures. Final rule.
    Drug Enforcement Administration (DEA), U.S. Department of Justice
    Fed Regist; 2007 Mar; 72(47):10925-8. PubMed ID: 17450656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Interim final rule with request for comments.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2009 Apr; 74(64):15595-625. PubMed ID: 19507319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Sep; 69(188):58950-3. PubMed ID: 15455477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should the DEA conduct a "patient impact assessment" when promulgating new restrictions on controlled substance distribution?
    Brushwood DB
    J Pain Palliat Care Pharmacother; 2008; 22(4):322-6. PubMed ID: 21923319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exemption from import/export requirements for personal medical use. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Sep; 69(177):55343-7. PubMed ID: 15366181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of Controlled Substance Prescribing: An Overview for Certified Nurse-Midwives and Certified Midwives.
    Osborne K
    J Midwifery Womens Health; 2017 May; 62(3):341-347. PubMed ID: 28544336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Drug Enforcement Agency's position on "constructive transfer" under the Controlled Substances Act.
    Pore RD
    Int J Pharm Compd; 2012; 16(6):446-50. PubMed ID: 23259358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Child support enforcement program; medical support enforcement--Office of Child Support Enforcement. Notice of Proposed rulemaking.
    Fed Regist; 1983 Jul; 48(146):34302-6. PubMed ID: 10299123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(144):43355-7. PubMed ID: 18949877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulations implementing the Federal Coal Mine Health and Safety Act of 1969, as amended. Employment Standards Administration, Labor. Final rule.
    Fed Regist; 2000 Dec; 65(245):79920-80107. PubMed ID: 11503734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Information on foreign chain of distribution for ephedrine, pseudoephedrine, and phenylpropanolamine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Mar; 75(43):10168-72. PubMed ID: 20383917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacist involvement in emergency room services.
    Culbertson V; Anderson RJ
    Contemp Pharm Pract; 1981; 4(3):167-76. PubMed ID: 10252154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.